Deconstructing Myogen's market cap
Article Abstract:
Myogen, a biopharmaceutical company in Westminster, Colorado, focusing on cardiovascular diseases, was found to be the best performing stock in 2005. Enoximone, a phosphosiesterase 3 inhibitor used to treat chronic heart failure, darusentan, a selective endothelin receptor antagonist used to treat treatment-resistant hypertension, and embrisentan, an endothelin receptor antagonist developed to treat pulmonary arterial hypertension (PAH), are three main products of Myogen that are under clinical trial.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
Are small biotechs still underselling themselves?
Article Abstract:
The future of a small biotech company, AtheroGenics, could become very bright if its lead compound, small molecule AGI-1067, passes through phase 3 trials for patients with atherosclerotic plaques. If the outcome of the trial is positive, the $50 million licensing bet that AstraZeneca made on AtheroGenics in December 2005 might prove to be a cheap gamble as AtheroGenics could otherwise have got almost $1 billion out of the deal.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
Niche indications could drive higher valuations
Article Abstract:
Gilead, a California based company is all set to purchase Colorado based Myogen which could demonstrate that companies with niche applications are becoming more attractive to better established biopharmaceutical companies. It is supposed that as a result of this, increased valuation for those niche biotech companies could follow.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Production of a recombinant bacterial lipoprotein in higher plant chloroplasts. Regulating transgenic crops sensibly: Lessons from plant breeding, biotechnology and genomics
- Abstracts: Boeing makes money with Israeli missile partnership. Faster Boeing communications may boost net-centric operations
- Abstracts: Venture capital distributions: short-run and long-run reactions. What do entrepreneurs pay for venture capital affiliation?
- Abstracts: Impact of warrant introductions on the behavior of underlying stocks: Australian evidence. Coming stateside
- Abstracts: Budget shock sparks fears over trusts. When regulation causes more problems than solutions. Brown's tax gap crusade